Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in Allergic Rhinitis
NCT06525597Phase 2Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Sep 2024
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR) comparing Stapokibart Group with Placebo Group (2 arms). Primary endpoint: Reflective Total Nasal Symptom Score at 4 weeks. Started Sep 2024; status: recruiting.
02
Drugs
stapokibart
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06525597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525597.